| 2025-12-31 | Stryker Corporation | $116 | Long term medical supply or device loan | In-kind items and services | OVERBED TABLE TRU-FIT Device, FURNITURE | | 2025 |
| 2025-12-31 | Novartis Pharmaceuticals Corporation | $57 | Research payment | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 |
| 2025-12-31 | Stryker Corporation | $35 | Debt forgiveness | Cash or cash equivalent | | | 2025 |
| 2025-12-17 | Aesculap Implant Systems, LLC | $1,015 | Debt forgiveness | Cash or cash equivalent | | | 2025 |
| 2025-11-20 | Abbott Laboratories | $467 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2025 |
| 2025-11-05 | AstraZeneca Pharmaceuticals LP | $6,900 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin in Acute Decompensated Heart Failure | 2025 |
| 2025-10-27 | Novartis Pharmaceuticals Corporation | $348 | Research payment | In-kind items and services | | A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participa | 2025 |
| 2025-09-15 | Novartis Pharmaceuticals Corporation | $5,006 | Research payment | Cash or cash equivalent | | A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participa | 2025 |
| 2025-08-19 | Novartis Pharmaceuticals Corporation | $900 | Research payment | Cash or cash equivalent | | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 |
| 2025-07-11 | E.R. Squibb & Sons, L.L.C. | $656 | Research payment | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes | 2025 |
| 2025-07-11 | PFIZER INC. | $34 | Research payment | Cash or cash equivalent | | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 |
| 2025-05-01 | Novocure Inc. | $2,500 | Research payment | Cash or cash equivalent | | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2025 |
| 2025-04-10 | Abbott Laboratories | $297 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2025 |
| 2025-04-10 | Abbott Laboratories | $27 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2025 |
| 2025-04-01 | PFIZER INC. | $66 | Research payment | Cash or cash equivalent | | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 |
| 2025-03-31 | Novartis Pharmaceuticals Corporation | $59 | Research payment | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 |
| 2025-03-25 | Genentech, Inc. | $68,334 | Research payment | Cash or cash equivalent | Xofluza Drug, Virology & Specialty Care | The COMBO 1 Trial | 2025 |
| 2025-01-09 | Novocure Inc. | $3,066 | Research payment | Cash or cash equivalent | | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2025 |
| 2025-01-09 | PFIZER INC. | $841 | Research payment | Cash or cash equivalent | | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 |
| 2025-01-09 | Novocure Inc. | $544 | Research payment | Cash or cash equivalent | | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2025 |
Comments